In a groundbreaking moment for genetic medicine, a six-month-old infant named KJ became the first person in the world to successfully receive a personalized CRISPR-based gene editing treatment for a rare and previously incurable condition. Developed by a research team from the Children’s Hospital of Philadelphia (CHOP) and Penn Medicine, this experimental therapy has not only saved his life but also opened the door for a new paradigm in the treatment of rare diseases.
A Lifechanging Diagnosis
KJ was born with a severe form of carbamoyl phosphate synthetase I deficiency (CPS1), an ultra-rare genetic disorder that disrupts the body’s ability to safely remove excess nitrogen. Normally, the human body converts nitrogen into urea, which is then excreted through urine. But in individuals with CPS1 deficiency, a key enzyme in the urea cycle is missing, causing toxic levels of ammonia to accumulate in the bloodstream. This condition can lead to brain damage, liver failure, and ultimately death, often within the first days or weeks of life if not aggressively managed.
In KJ’s case, immediate intervention was necessary. Doctors placed him on a stringent low-protein diet and administered nitrogen-scavenging medications to manage ammonia levels. But such measures, while temporarily stabilizing, are not curative. The only long-term solution traditionally available is a liver transplant, which comes with its own risks and limitations, particularly for infants too young or fragile to undergo major surgery.
The prognosis for KJ was grim—until a team of researchers led by Dr. Rebecca Ahrens-Nicklas, a pediatric geneticist and director of CHOP’s Gene Therapy for Inherited Metabolic Disorders program, and Dr. Kiran Musunuru, a professor of cardiovascular medicine and expert in genome editing at the University of Pennsylvania, proposed an audacious alternative: a gene editing therapy designed exclusively for KJ’s unique mutation.
Revolutionizing Gene Therapy for Rare Diseases
Their approach employed a refined technique within the CRISPR genome editing family known as base editing, which allows scientists to chemically convert a single DNA letter (or “base”) into another without cutting the DNA double helix—a key difference from traditional CRISPR, which introduces breaks in the genetic code. This precision reduces the risk of unintended mutations and is especially useful for correcting specific, known point mutations like the one that causes KJ’s disorder.
Using genetic sequencing data gathered shortly after his birth, the team rapidly designed and manufactured a personalized base editing treatment targeting KJ’s specific genetic variant of CPS1. The gene editor was encapsulated in lipid nanoparticles—similar to those used in mRNA COVID-19 vaccines—to ensure efficient delivery to liver cells, where the urea cycle enzymes are produced.
What makes this achievement particularly remarkable is the speed at which it was developed. The entire therapy—from design to delivery—was created within six months. This pace is virtually unheard of in traditional drug development timelines, which can span years, if not decades. The reason such speed was possible, according to Dr. Musunuru, lies in both the technological maturity of CRISPR tools and the emergence of flexible, patient-specific development platforms.
Behind the Scenes Peek at a Scientific Breakthrough
KJ received his first infusion of the therapy in February 2024, followed by additional doses in March and April. Since then, the changes in his condition have been nothing short of dramatic. According to follow-up evaluations, he has shown significant improvement in his metabolic health. He is now able to consume more dietary protein—previously a major threat to his system—and has been weaned off some of the medications that had been essential to controlling his ammonia levels. Importantly, he has been able to recover from routine childhood illnesses without experiencing dangerous spikes in ammonia, a previously life-threatening scenario.
Equally crucial is the fact that KJ has tolerated the therapy without any serious side effects to date. This safety profile further supports the viability of base editing as a potentially transformative tool in pediatric medicine, especially for children with life-threatening genetic diseases for whom time is critical.
The case was formally detailed in a peer-reviewed study published in The New England Journal of Medicine, which has been widely heralded by the scientific community as a milestone in the evolution of personalized gene therapy. The study not only documents the successful administration of the treatment, but also outlines the methodology and ethical framework that guided the project—especially important since this represents a first-in-human intervention with a custom-built therapy.
Pioneering a Personalized Approach
Dr. Ahrens-Nicklas highlighted the collaborative nature of the project as key to its success. “Years and years of progress in gene editing and collaboration between researchers and clinicians made this moment possible,” she said. “While KJ is just one patient, we hope he is the first of many to benefit from a methodology that can be scaled to fit an individual patient’s needs.”
Indeed, scaling this model is a major goal of the broader scientific initiative of which the project is a part. Both Ahrens-Nicklas and Musunuru are members of the NIH-funded Somatic Cell Genome Editing Consortium, a multi-institutional effort to advance genome editing applications and improve safety for future therapies. This body supports collaborative research projects aimed at creating platforms that can be adapted quickly to treat rare genetic conditions in real time.
The traditional pharmaceutical model has long prioritized diseases with large patient populations due to the financial viability of scaling treatments for the masses. As a result, rare disease patients—often called “orphans” of the medical system—have historically been underserved. However, technological advances in genomic medicine, along with increased regulatory flexibility and support from public research agencies, are beginning to change that dynamic.
Musunuru emphasized the implications of KJ’s case for the future of healthcare: “The promise of gene therapy that we’ve heard about for decades is coming to fruition, and it’s going to utterly transform the way we approach medicine.” Instead of treating symptoms, medicine can now, in select cases, rewrite the genetic instruction manual at the root of disease.
For KJ’s parents, Nicole and Kyle Muldoon, this medical milestone is deeply personal. Their journey began with the terror of watching their newborn struggle to survive and has evolved into a story of hope, resilience, and scientific wonder.
“We wanted to figure out how we were going to support him and how we were going to get him to the point where he can do all the things a normal kid should be able to do,” said Nicole. “We thought it was our responsibility to help our child, so when the doctors came to us with their idea, we put our trust in them in the hopes that it could help not just KJ but other families in our position.”
Their decision to participate in the experimental treatment was not taken lightly. But that courage may ultimately benefit more than just their son. As regulatory frameworks evolve and gene editing tools continue to mature, families grappling with rare genetic diseases may one day have access to personalized cures designed with the same urgency and precision that saved KJ’s life.
Message of Hope
“We’re so excited to be able to finally be together at home, so that KJ can be with his siblings, and we can finally take a deep breath,” Kyle added, expressing the sense of relief that has come with seeing their son recover.
Though KJ will require lifelong monitoring, the success of this therapy offers something rare in the world of genetic disease—a second chance at life. And for the millions of families worldwide facing similarly rare and devastating diagnoses, it offers something equally powerful: hope.
Recommended For You
